Thomas Rhys H, Cunningham Mark O
Institute of Neuroscience, Newcastle University, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK
School of Medicine, Discipline of Physiology, University of Dublin Trinity College, Dublin, Ireland.
Pract Neurol. 2018 Dec;18(6):465-471. doi: 10.1136/practneurol-2018-002058. Epub 2018 Oct 18.
Click here to listen to the Podcast The one-third of people who do not gain seizure control through current treatment options need a revolution in epilepsy therapeutics. The general population appears to be showing a fundamental and rapid shift in its opinion regarding cannabis and cannabis-related drugs. It is quite possible that cannabidiol, licensed in the USA for treating rare genetic epilepsies, may open the door for the widespread legalisation of recreational cannabis. It is important that neurologists understand the difference between artisanal cannabidiol products available legally on the high street and the cannabidiol medications that have strong trial evidence. In the UK in 2018 there are multiple high-profile reports of the response of children taking cannabis-derived medication, meaning that neurologists are commonly asked questions about these treatments in clinic. We address what an adult neurologist needs to know now, ahead of the likely licensing of Epidiolex in the UK in 2019.
点击此处收听播客。三分之一的患者目前通过现有治疗方案无法实现癫痫控制，他们需要一场癫痫治疗的革命。普通民众对大麻及与大麻相关药物的看法似乎正在发生根本性的快速转变。在美国已获许可用于治疗罕见遗传性癫痫的大麻二酚，很有可能为休闲大麻的广泛合法化打开大门。神经科医生必须了解在商业街合法可得的手工大麻二酚产品与有强有力试验证据的大麻二酚药物之间的区别，这一点很重要。2018年在英国，有多起关于服用大麻衍生药物的儿童反应的备受瞩目的报道，这意味着神经科医生在诊所里经常会被问到有关这些治疗的问题。在2019年英国可能批准Epidiolex之前，我们阐述了成年神经科医生现在需要了解的内容。
